Qiang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qiang Wang has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Torkel B. Brismar
Karolinska Institutet
10 shared publications - Ernesto Sparrelid
Department of Clinical Science, Intervention and Technology, Division of Surgery and Oncology, Karolinska Institutet, Stockholm, Sweden
9 shared publications - Kuansheng Ma
Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing, China
5 shared publications Torkel B. Brismar
Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Medical Imaging and Technology, Karolinska Institutet, Stockholm, Sweden; Department of Radiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
5 shared publicationsAnrong Wang
Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publicationsChangfeng Li
Institution of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing, China
3 shared publications
Latest Publications
- Open Access
Liver functional radiomics of gadoxetic acid-enhanced magnetic resonance imaging: A proof-of-concept study
Objectives: This study aimed to identify reproducible and repeatable radiomics features (RF) of gadoxetic acid-enhanced MRI that correlate with liver function. Methods: This study included 10 patients with colorectal liver metastasis who received a right hepatectomy and were prospectively recruited. Before surgery, all patients underwent indocyanine green (ICG) retention test, hepatobiliary scintigraphy (HBS) exam and gadoxetic acid-enhanced MRI. RF were extracted from the non-tumoral liver parenchyma at the MRI images before contrast injection and the hepatobiliary phase. Delta-RF were calculated by RFs of hepatobiliary phase subtract those before contrast injection. ICG-R15, HBS results, and kinetic growth rate (KGR) of the future liver remnant volume were used as quantitative indices of liver function. Reproducible and repeatable RF were identified via inter- and intraclass correlation analysis with a coefficient threshold of 0.80. Correlations between RF/delta-RF and the three liver function indices (ICG-R15, HBS and KGR) were evaluated by Spearman correlation analysis. Results: One hundred and seven RFs were extracted from each MRI phase (214 in total and 107 derived delta RFs). With inter- and intraclass correlation analysis, 60 reproducible and repeatable RFs were identified. After removing RFs with higher correlation coefficients, 12 RF from images before contrast injection, 23 RF from hepatobiliary phase, 29 delta-RF were identified significantly correlated with the liver function metrics (ICG-R15, HBS and KGR). Conclusions: A set of reproducible and repeatable radiomics features of gadoxetic acidenhanced MRI which were associated with liver function were identified. These features can be adopted for future liver function-related radiomics research.
Open AccessLiver functional radiomics of gadoxetic acid-enhanced magnetic resonance imaging: A proof-of-concept study
Objectives: This study aimed to identify reproducible and repeatable radiomics features (RF) of gadoxetic acid-enhanced MRI that correlate with liver function. Methods: This study included 10 patients with colorectal liver metastasis who received a right hepatectomy and were prospectively recruited. Before surgery, all patients underwent indocyanine green (ICG) retention test, hepatobiliary scintigraphy (HBS) exam and gadoxetic acid-enhanced MRI. RF were extracted from the non-tumoral liver parenchyma at the MRI images before contrast injection and the hepatobiliary phase. Delta-RF were calculated by RFs of hepatobiliary phase subtract those before contrast injection. ICG-R15, HBS results, and kinetic growth rate (KGR) of the future liver remnant volume were used as quantitative indices of liver function. Reproducible and repeatable RF were identified via inter- and intraclass correlation analysis with a coefficient threshold of 0.80. Correlations between RF/delta-RF and the three liver function indices (ICG-R15, HBS and KGR) were evaluated by Spearman correlation analysis. Results: One hundred and seven RFs were extracted from each MRI phase (214 in total and 107 derived delta RFs). With inter- and intraclass correlation analysis, 60 reproducible and repeatable RFs were identified. After removing RFs with higher correlation coefficients, 12 RF from images before contrast injection, 23 RF from hepatobiliary phase, 29 delta-RF were identified significantly correlated with the liver function metrics (ICG-R15, HBS and KGR). Conclusions: A set of reproducible and repeatable radiomics features of gadoxetic acidenhanced MRI which were associated with liver function were identified. These features can be adopted for future liver function-related radiomics research.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-13
Predictive Value of Age-Adjusted Charlson Comorbidity Index on Survival Outcomes of Hepatocellular Carcinoma Patients with Comorbidities Undergoing Radiofrequency Ablation
This study aimed to explore the predictive value of Age-Adjusted Charlson Comorbidity Index (ACCI) on survival outcomes in patients with hepatocellular carcinoma (HCC) and comorbidities undergoing radiofrequency ablation (RFA). This study is a retrospective, single-center study which included 158 patients with HCC newly diagnosed at our center from January 2015 to December 2021 who had comorbidities prior to RFA treatment. Patients were divided into two groups (≤4 and >4) according to the optimal cutoff value of ACCI determined by X-tile analysis based on overall survival (OS), and comprehensive clinical, laboratory, and tumor characteristic data were collected. The primary endpoints were OS and recurrence-free survival (RFS), analyzed using the Kaplan-Meier method and Cox proportional hazards model. Patients in the high ACCI group (>4) were independently associated with worse OS and RFS compared to those in the low ACCI group (≤4). Multivariate Cox analysis confirmed that ACCI >4 was an independent risk factor for both OS and RFS, with hazard ratios (HR) of 2.07 and 2.05, respectively. In addition to ACCI, other independent predictors for worse OS included tumor max-diameter (HR: 1.69, P < 0.001) and elevated level of preoperative α-fetoprotein (HR: 1.91, P = 0.007), while preoperative albumin (HR: 0.93, P=0.001) was a significant protective factor for OS. For RFS, significant risk factors included tumor max-diameter (HR: 1.79, P < 0.001) and prothrombin time ≥ 13 seconds (HR: 2.38, P = 0.001). ACCI may serve as a useful prognostic predictor for survival outcomes in HCC patients with comorbidities undergoing RFA.
- 1 April 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-13
Open AccessPredictive Value of Age-Adjusted Charlson Comorbidity Index on Survival Outcomes of Hepatocellular Carcinoma Patients with Comorbidities Undergoing Radiofrequency Ablation
This study aimed to explore the predictive value of Age-Adjusted Charlson Comorbidity Index (ACCI) on survival outcomes in patients with hepatocellular carcinoma (HCC) and comorbidities undergoing radiofrequency ablation (RFA). This study is a retrospective, single-center study which included 158 patients with HCC newly diagnosed at our center from January 2015 to December 2021 who had comorbidities prior to RFA treatment. Patients were divided into two groups (≤4 and >4) according to the optimal cutoff value of ACCI determined by X-tile analysis based on overall survival (OS), and comprehensive clinical, laboratory, and tumor characteristic data were collected. The primary endpoints were OS and recurrence-free survival (RFS), analyzed using the Kaplan-Meier method and Cox proportional hazards model. Patients in the high ACCI group (>4) were independently associated with worse OS and RFS compared to those in the low ACCI group (≤4). Multivariate Cox analysis confirmed that ACCI >4 was an independent risk factor for both OS and RFS, with hazard ratios (HR) of 2.07 and 2.05, respectively. In addition to ACCI, other independent predictors for worse OS included tumor max-diameter (HR: 1.69, P < 0.001) and elevated level of preoperative α-fetoprotein (HR: 1.91, P = 0.007), while preoperative albumin (HR: 0.93, P=0.001) was a significant protective factor for OS. For RFS, significant risk factors included tumor max-diameter (HR: 1.79, P < 0.001) and prothrombin time ≥ 13 seconds (HR: 2.38, P = 0.001). ACCI may serve as a useful prognostic predictor for survival outcomes in HCC patients with comorbidities undergoing RFA.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-11
Long-Term Outcome of No-Touch Radiofrequency Ablation for Treating AFP-Positive Small Hepatocellular Carcinoma
This study aimed to evaluate the short- and long-term efficacy of no-touch radiofrequency ablation (NT-RFA) in treating patients with AFP-positive, solitary hepatocellular carcinoma (HCC) with a diameter of ≤ 3cm, and to assess its effect on AFP levels. A retrospective analysis was conducted on 245 AFP-positive HCC patients treated with NT-RFA (n=78) and Conventional RFA (C-RFA) (n=167) at our center between 2015 and 2023. The changes of AFP levels were compared. Statistical analysis was conducted on the overall survival(OS), recurrence free survival(RFS), and tumor recurrence status of the two groups at 1 to 5-years post-RFA. The decrease in postoperative AFP levels was significantly greater in the NT-RFA group than that in the C-RFA group (P=0.009), and the postoperative AFP seronegative rate in the NT-RFA group was significantly higher than that in the C-RFA group (P=0.020). The OS rates at 1-, 3-, and 5-years were 100.00%, 71.07%, and 54.07% for NT-RFA group, while 95.21%, 62.06%, and 30.80% for C-RFA group. Significant differences existed between the two groups (P=0.026). The 1-, 3-, and 5-year RFS rates in the NT-RFA group were 79.49%, 46.36%, and 29.96%, while 65.87%, 30.99%, and 21.20% in the C-RFA group. Significant differences existed between the two groups (P=0.025). The 1-, 3-, and 5-year local tumor progression-free survival (LTP-FS) rates were 89.67%, 83.31%, 81.06% in the NT-RFA group and 79.01%, 64.61%, 63.10% in the C-RFA group. Significant differences existed between the two groups (P=0.002). But there was no significant difference in intrahepatic distant recurrence-free survival (IDR-FS) between the two groups (P=0.819). Compared with C-RFA, NT-RFA treatment for AFP positive HCC ≤ 3cm is more effective in reducing postoperative AFP levels and improving the rate of AFP conversion to negative. Meanwhile, NT-RFA significantly increased RFS and OS. It can replace C-RFA as the primary treatment method for AFP-positive small HCC.
- 1 April 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-11
Open AccessLong-Term Outcome of No-Touch Radiofrequency Ablation for Treating AFP-Positive Small Hepatocellular Carcinoma
This study aimed to evaluate the short- and long-term efficacy of no-touch radiofrequency ablation (NT-RFA) in treating patients with AFP-positive, solitary hepatocellular carcinoma (HCC) with a diameter of ≤ 3cm, and to assess its effect on AFP levels. A retrospective analysis was conducted on 245 AFP-positive HCC patients treated with NT-RFA (n=78) and Conventional RFA (C-RFA) (n=167) at our center between 2015 and 2023. The changes of AFP levels were compared. Statistical analysis was conducted on the overall survival(OS), recurrence free survival(RFS), and tumor recurrence status of the two groups at 1 to 5-years post-RFA. The decrease in postoperative AFP levels was significantly greater in the NT-RFA group than that in the C-RFA group (P=0.009), and the postoperative AFP seronegative rate in the NT-RFA group was significantly higher than that in the C-RFA group (P=0.020). The OS rates at 1-, 3-, and 5-years were 100.00%, 71.07%, and 54.07% for NT-RFA group, while 95.21%, 62.06%, and 30.80% for C-RFA group. Significant differences existed between the two groups (P=0.026). The 1-, 3-, and 5-year RFS rates in the NT-RFA group were 79.49%, 46.36%, and 29.96%, while 65.87%, 30.99%, and 21.20% in the C-RFA group. Significant differences existed between the two groups (P=0.025). The 1-, 3-, and 5-year local tumor progression-free survival (LTP-FS) rates were 89.67%, 83.31%, 81.06% in the NT-RFA group and 79.01%, 64.61%, 63.10% in the C-RFA group. Significant differences existed between the two groups (P=0.002). But there was no significant difference in intrahepatic distant recurrence-free survival (IDR-FS) between the two groups (P=0.819). Compared with C-RFA, NT-RFA treatment for AFP positive HCC ≤ 3cm is more effective in reducing postoperative AFP levels and improving the rate of AFP conversion to negative. Meanwhile, NT-RFA significantly increased RFS and OS. It can replace C-RFA as the primary treatment method for AFP-positive small HCC.
- Open Access
- 22 March 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 199, 112811
Tumor burden in patients with colorectal liver metastasis undergoing hepatectomy: A head-to-head comparison of four prognostic systems
- 22 March 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 199, 112811
Open AccessTumor burden in patients with colorectal liver metastasis undergoing hepatectomy: A head-to-head comparison of four prognostic systems
- Open Access
- 6 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 165-173
BCLC classification and AI-based image quantification: What is meant to be will come together – but how and when?
- 6 March 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (1) , 165-173
Open AccessBCLC classification and AI-based image quantification: What is meant to be will come together – but how and when?
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-13
Short- and Long-Term Outcomes of Radiofrequency Ablation for Early Hepatocellular Carcinoma with Liver Dysfunction
This study aimed to report the short- and long-term outcomes of radiofrequency ablation (RFA) for the treatment of patients with early hepatocellular carcinoma (HCC) with different levels of liver dysfunction. This retrospective study included early HCC patients with Child-Pugh score (CPS) ≥ 7 cirrhosis who underwent percutaneous RFA at our center. The short-term efficacy of RFA was evaluated based on postoperative technical success, effectiveness, and complications, and long-term efficacy was evaluated based on recurrence-free survival (RFS) and overall survival (OS). The impact of liver dysfunction on both outcomes was explored. In total, 176 patients (median age, 57 years; 149 males) were included. The technical success rate, technical effectiveness, and incidence of postoperative major complications were 96.6%, 97.7%, and 3.4%, respectively. There were no significant differences between the groups divided according to CPS. The 1-, 3-, and 5-year RFS rates were 54.1%, 28.8%, and 16.8%, respectively, no significant differences were observed between the groups divided by Child-Pugh score (p = 0.057), Albumin-Bilirubin grade (p = 0.170), or Model for End-stage Liver Disease score (p=0.210). The 1-, 3-, and 5-year OS rates were 91.3%, 67.1%, and 58.5%, respectively, and OS decreased as ALBI grade increased (p = 0.015). Multivariate Cox analysis demonstrated that male patient (hazard ratio, 2.31; p = 0.013) and recurrent HCC (hazard ratio, 2.347; p < 0.001) were independent predictive factors for RFS; hypertension (hazard ratio, 2.828; p = 0.042) and tumor number (hazard ratio, 2.445; p = 0.011) were independent predictive factors for OS, respectively. Radiofrequency ablation is safe and effective for early HCC patients with early hepatocellular carcinoma and liver dysfunction.
- 1 March 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-13
Open AccessShort- and Long-Term Outcomes of Radiofrequency Ablation for Early Hepatocellular Carcinoma with Liver Dysfunction
This study aimed to report the short- and long-term outcomes of radiofrequency ablation (RFA) for the treatment of patients with early hepatocellular carcinoma (HCC) with different levels of liver dysfunction. This retrospective study included early HCC patients with Child-Pugh score (CPS) ≥ 7 cirrhosis who underwent percutaneous RFA at our center. The short-term efficacy of RFA was evaluated based on postoperative technical success, effectiveness, and complications, and long-term efficacy was evaluated based on recurrence-free survival (RFS) and overall survival (OS). The impact of liver dysfunction on both outcomes was explored. In total, 176 patients (median age, 57 years; 149 males) were included. The technical success rate, technical effectiveness, and incidence of postoperative major complications were 96.6%, 97.7%, and 3.4%, respectively. There were no significant differences between the groups divided according to CPS. The 1-, 3-, and 5-year RFS rates were 54.1%, 28.8%, and 16.8%, respectively, no significant differences were observed between the groups divided by Child-Pugh score (p = 0.057), Albumin-Bilirubin grade (p = 0.170), or Model for End-stage Liver Disease score (p=0.210). The 1-, 3-, and 5-year OS rates were 91.3%, 67.1%, and 58.5%, respectively, and OS decreased as ALBI grade increased (p = 0.015). Multivariate Cox analysis demonstrated that male patient (hazard ratio, 2.31; p = 0.013) and recurrent HCC (hazard ratio, 2.347; p < 0.001) were independent predictive factors for RFS; hypertension (hazard ratio, 2.828; p = 0.042) and tumor number (hazard ratio, 2.445; p = 0.011) were independent predictive factors for OS, respectively. Radiofrequency ablation is safe and effective for early HCC patients with early hepatocellular carcinoma and liver dysfunction.
- 10 January 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (3) , 111402
Improved risk stratification in patients with colorectal liver metastases by incorporating volumetric body composition analysis
- 10 January 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (3) , 111402
Improved risk stratification in patients with colorectal liver metastases by incorporating volumetric body composition analysis
- Open Access
- 10 December 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (3) , 1795-1807
Development and External Validation of a Combined Clinical–Radiomic Model for Predicting Insufficient Hypertrophy of the Future Liver Remnant following Portal Vein Embolization
Objectives: This study aimed to develop and externally validate a model for predicting insufficient future liver remnant (FLR) hypertrophy after portal vein embolization (PVE) based on clinical factors and radiomics of pretreatment computed tomography (CT) Patients and methods: Clinical information and CT scans of 241 consecutive patients from three Swedish centers were retrospectively collected. One center (120 patients) was applied for model development, and the other two (59 and 62 patients) as test cohorts. Logistic regression analysis was adopted for clinical model development. A FLR radiomics signature was constructed from the CT images using the support vector machine. A model combining clinical factors and FLR radiomics signature was developed. Area under the curve (AUC) was adopted for predictive performance evaluation Results: Three independent clinical factors were identified for model construction: pretreatment standardized FLR (odds ratio (OR): 1.12, 95% confidence interval (CI): 1.04–1.20), alanine transaminase (ALT) level (OR: 0.98, 95% CI: 0.97–0.99), and PVE material (OR: 0.27, 95% CI: 0.08–0.87). This clinical model showed an AUC of 0.75, 0.71, and 0.68 in the three cohorts, respectively. A total of 833 radiomics features were extracted, and after feature dimension reduction, 16 features were selected for FLR radiomics signature construction. When adding it to the clinical model, the AUC of the combined model increased to 0.80, 0.76, and 0.72, respectively. However, the increase was not significant. Conclusions: Pretreatment CT radiomics showed added value to the clinical model for predicting FLR hypertrophy following PVE. Although not reaching statistically significant, the evolving radiomics holds a potential to supplement traditional predictors of FLR hypertrophy.
- 10 December 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (3) , 1795-1807
Open AccessDevelopment and External Validation of a Combined Clinical–Radiomic Model for Predicting Insufficient Hypertrophy of the Future Liver Remnant following Portal Vein Embolization
Objectives: This study aimed to develop and externally validate a model for predicting insufficient future liver remnant (FLR) hypertrophy after portal vein embolization (PVE) based on clinical factors and radiomics of pretreatment computed tomography (CT) Patients and methods: Clinical information and CT scans of 241 consecutive patients from three Swedish centers were retrospectively collected. One center (120 patients) was applied for model development, and the other two (59 and 62 patients) as test cohorts. Logistic regression analysis was adopted for clinical model development. A FLR radiomics signature was constructed from the CT images using the support vector machine. A model combining clinical factors and FLR radiomics signature was developed. Area under the curve (AUC) was adopted for predictive performance evaluation Results: Three independent clinical factors were identified for model construction: pretreatment standardized FLR (odds ratio (OR): 1.12, 95% confidence interval (CI): 1.04–1.20), alanine transaminase (ALT) level (OR: 0.98, 95% CI: 0.97–0.99), and PVE material (OR: 0.27, 95% CI: 0.08–0.87). This clinical model showed an AUC of 0.75, 0.71, and 0.68 in the three cohorts, respectively. A total of 833 radiomics features were extracted, and after feature dimension reduction, 16 features were selected for FLR radiomics signature construction. When adding it to the clinical model, the AUC of the combined model increased to 0.80, 0.76, and 0.72, respectively. However, the increase was not significant. Conclusions: Pretreatment CT radiomics showed added value to the clinical model for predicting FLR hypertrophy following PVE. Although not reaching statistically significant, the evolving radiomics holds a potential to supplement traditional predictors of FLR hypertrophy.
- Open Access
- 7 December 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (3) , 1833-1834
ASO Author Reflections: Added Value of Pretreatment CT Radiomics for Accurate Prediction of Liver Hypertrophy Following Portal Vein Embolization
- 7 December 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 32 (3) , 1833-1834
Open AccessASO Author Reflections: Added Value of Pretreatment CT Radiomics for Accurate Prediction of Liver Hypertrophy Following Portal Vein Embolization